Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06178913
Other study ID # 4-2023-0549
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 10, 2023
Est. completion date September 2024

Study information

Verified date December 2023
Source Yonsei University
Contact Young Ae Kang
Phone +82-2228-1954
Email mdkang@yuhs.ac
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study goal is to develop exercise intervention methods to improve the prognosis and quality of life of patients with non-tuberculous mycobacterial lung disease and to confirm the effectiveness of exercise intervention. This prospective study is scheduled to be conducted as a pre-post single-arm feasibility trial, targeting a total of 50 subjects.


Description:

1. After confirming the intention to participate in the study for patients with non-tuberculous mycobacterial lung disease who meet the selection criteria, basic personal information and clinical history information are collected. 2. When three people are recruited, they are organized into one group and begin a four-week exercise program. A total of 17 groups will be recruited and 50 people will be registered, and within 1 week before and after the start of the exercise program, VO2 max, physical function (6MWT, 30s sit to stand, SPPB, Handgrip strength), Baseline PFT, Laboratory test, Quality of life test (QOL) -B, CAT) is performed. 3. Once a week for 4 weeks, full-body strength training and aerobic exercise are performed for 60 minutes with an exercise expert (supervised exercise), and the remaining 6 days a week are home-based exercises, in which the subject exercises independently at home. Write it down in participants exercise diary. 4. VO2 max, physical function (6MWT, 30s sit to stand, SPPB, handgrip strength), PFT, laboratory test, and quality of life test (QOL-B, CAT) are conducted again within one week before and after the exercise intervention is completed.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date September 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 19 Years to 80 Years
Eligibility Inclusion Criteria: Adults aged 19 to 80 years diagnosed with non-tuberculous mycobacterial lung disease according to the ATS/IDSA guideline, Patients with respiratory symptoms (cough, phlegm, difficulty breathing, etc.) at the time of selection, Patients who understand the purpose of the clinical study and voluntarily agree to participate in this clinical study Exclusion Criteria: Patients diagnosed with cardiovascular disease (Angina, HFrEF, arrhythmia, history of heart valve surgery, etc.), Patients who have had massive hemoptysis within the last 3 months, Patients who have difficulty moving freely due to musculoskeletal problems (osteoarthritis, intervertebral disc herniation, spinal stenosis, etc.), Patients who cannot read the consent form (e.g. illiterate, foreigner, etc.)

Study Design


Intervention

Other:
Exercise intervention
The exercise intervention method is a circuit training method that combines strength training and aerobic exercise forms and consists of a total of 12 movements. Performing movements 1 to 12 in order is 1 set. After completing the set, when the heart rate returns to the plateau (less than 59% of maximum heart rate), proceed to the next set, for a total of 3 sets.

Locations

Country Name City State
Korea, Republic of Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine Seoul

Sponsors (1)

Lead Sponsor Collaborator
Yonsei University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary VO2max The patient wears a mask that transmits inhalation and exhalation to a gas analyzer on the treadmill and a heart rate monitor that measures heart rate. The treadmill gradually increases the incline and increases the speed. When the patient runs as far as they can run and raises their hand to show the measurer, the patient's VO2max is measured by measuring the maximum amount of oxygen that can be taken in and heart rate. within the first 1 week (plus or minus 1 week) after the end of exercise intervention
Secondary The 6-Minute Walk Test The 6-Minute Walk Test, 30-Second Sit-to-Stand, Short Physical Performance Battery, and Muscular Strength (Handgrip strength in kilograms) are employed to assess the physical ability of our study participants. within the first 1 week (plus or minus 1 week) after the end of exercise intervention
Secondary 30-Second Sit-to-Stand The 6-Minute Walk Test, 30-Second Sit-to-Stand, Short Physical Performance Battery, and Muscular Strength (Handgrip strength in kilograms) are employed to assess the physical ability of our study participants. within the first 1 week (plus or minus 1 week) after the end of exercise intervention
Secondary Short Physical Performance Battery The 6-Minute Walk Test, 30-Second Sit-to-Stand, Short Physical Performance Battery, and Muscular Strength (Handgrip strength in kilograms) are employed to assess the physical ability of our study participants. within the first 1 week (plus or minus 1 week) after the end of exercise intervention
Secondary Muscular strength (Handgrip strength in kilograms) The 6-Minute Walk Test, 30-Second Sit-to-Stand, Short Physical Performance Battery, and Muscular Strength (Handgrip strength in kilograms) are employed to assess the physical ability of our study participants. within the first 1 week (plus or minus 1 week) after the end of exercise intervention
Secondary COPD Assessment Test The COPD Assessment Test and the Quality of Life-Bronchiectasis (QOL-B) questionnaire are used for evaluating the quality of life in our study participants. within the first 1 week (plus or minus 1 week) after the end of exercise intervention
Secondary the Quality of Life-Bronchiectasis (QOL-B) questionnaire The COPD Assessment Test and the Quality of Life-Bronchiectasis (QOL-B) questionnaire are used for evaluating the quality of life in our study participants. within the first 1 week (plus or minus 1 week) after the end of exercise intervention
Secondary forced vital capacity in percent Forced vital capacity in percent, forced expiratory volume exhaled in the first second in percent, the forced expiratory volume in 1 s/forced vital capacity ratio in percent, and bronchodilator response in percent are utilized to evaluate lung function in our study participants. within the first 1 week (plus or minus 1 week) after the end of exercise intervention
Secondary forced expiratory volume exhaled in the first second in percent Forced vital capacity in percent, forced expiratory volume exhaled in the first second in percent, the forced expiratory volume in 1 s/forced vital capacity ratio in percent, and bronchodilator response in percent are utilized to evaluate lung function in our study participants. within the first 1 week (plus or minus 1 week) after the end of exercise intervention
Secondary a forced expiratory volume in 1 s/forced vital capacity ratio in percent Forced vital capacity in percent, forced expiratory volume exhaled in the first second in percent, the forced expiratory volume in 1 s/forced vital capacity ratio in percent, and bronchodilator response in percent are utilized to evaluate lung function in our study participants. within the first 1 week (plus or minus 1 week) after the end of exercise intervention
Secondary bronchodilator response in percent Forced vital capacity in percent, forced expiratory volume exhaled in the first second in percent, the forced expiratory volume in 1 s/forced vital capacity ratio in percent, and bronchodilator response in percent are utilized to evaluate lung function in our study participants. within the first 1 week (plus or minus 1 week) after the end of exercise intervention
Secondary WBC count per microliter WBC count per microliter, hemoglobin in grams per deciliter, albumin in grams per deciliter, and CRP in milligrams per liter are used to assess inflammation, nutrition, and anemia status in our study participants. within the first 1 week (plus or minus 1 week) after the end of exercise intervention
Secondary hemoglobin in gram per deciliter WBC count per microliter, hemoglobin in grams per deciliter, albumin in grams per deciliter, and CRP in milligrams per liter are used to assess inflammation, nutrition, and anemia status in our study participants. within the first 1 week (plus or minus 1 week) after the end of exercise intervention
Secondary Albumin in gram per deciliter WBC count per microliter, hemoglobin in grams per deciliter, albumin in grams per deciliter, and CRP in milligrams per liter are used to assess inflammation, nutrition, and anemia status in our study participants. within the first 1 week (plus or minus 1 week) after the end of exercise intervention
Secondary CRP in miligram per liter WBC count per microliter, hemoglobin in grams per deciliter, albumin in grams per deciliter, and CRP in milligrams per liter are used to assess inflammation, nutrition, and anemia status in our study participants. within the first 1 week (plus or minus 1 week) after the end of exercise intervention
Secondary Body fat mass in kilogram Body fat mass in kilograms and skeletal muscle mass in kilograms are used to assess the amount of fat and muscle in our study participants. within the first 1 week (plus or minus 1 week) after the end of exercise intervention
Secondary skeletal muscle mass in kilogram Body fat mass in kilograms and skeletal muscle mass in kilograms are used to assess the amount of fat and muscle in our study participants. within the first 1 week (plus or minus 1 week) after the end of exercise intervention
See also
  Status Clinical Trial Phase
Recruiting NCT02779478 - Evaluation Of The Lung Microbiome In NTM Bronchiectasis
Recruiting NCT03957447 - Treat Early and Broad: Thermotherapy of Buruli Ulcer Integrated Into WHO-recommended Wound Management in West Africa
Active, not recruiting NCT00814827 - Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma
Completed NCT00600769 - Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM) Phase 4
Recruiting NCT03339063 - The Italian REgistry of Pulmonary Non-tuberculous mycobactEria